Roche Diagnostics  

As the world leader in point-of-care blood glucose testing*, Roche Point of Care brings together extensive hospital diagnostics experience, connectivity solutions and comprehensive resources, all backed by unparalleled sales and service support, to help you provide the best care possible. From the wireless meter, patented test strip technology and easy-to-use lancing devices to seamless IT integration, everything about the Accu-Chek Inform II system works together so you can do more for your patients by providing these advantages:

• Fast, reliable results in 5 seconds with over 150 integrity checks to help ensure accuracy
• Greater flexibility and efficiency
• Ongoing training and 24/7/365 technical support   

The CoaguChek^® Vantus system helps patients easily test their INR from home.

• Easy to use. Features make accurate self-testing as easy and as repeatable as possible, including full-color display with easy-to-use on-screen instructions.
• Seamless transfer of INR test results. No phone calls or manual entry on a web page required. Results are accurately reported via Bluetooth^® connectivity to CoaguChek Link.
• Electronic Health Record integration. INR results are automatically transferred from CoaguChek Link straight into a patient’s EHR.

• Expert training and support. CoaguChek Patient Services provides all self-testing supplies, as well as training, including e-learning and a face-to-face patient training course, and live technical support.  

The cobas u 601 urine analyzer offers throughput up to 240 samples/hour and makes strip and QC management easier with RFID technology. The built-in camera takes high-resolution images for strip result reading, which can differentiate intact and lysed erythrocytes up to 50 E/µL. Utilizing reflectance photometry and refractometry (SG), it incorporates automatic sample mixing prior to analysis, automated calibration(dry) every 28 days, and onboard water and waste containers. The cobas u 601 analyzer is the successor to the Urisys 2400^® analyzer, using the same proven Chemstrip^® technology that virtually eliminates Vitamin C interference. cobas u pack reagents, in a unique cassette design, contain 400 test strips with 14-day onboard stability.   

The cobas^® 8100 automated workflow series delivers automation without compromise by allowing you to customize the system and workflow to meet your lab’s unique needs. The innovative multilevel, bi-directional 3D intelligent sample transport design ensures efficient sample routing for multiple disciplines and predictable turnaround times during peak testing hours. The workflow your way concept enables you to choose workflows using primary, aliquot and mixed sample workflows. Online short-, mid- and long-term storage reduces manual touchpoints and ensures fast automated access to samples any time. The cobas^® 8100 automated workflow series delivers the quality and reliability you expect, with customization for low-, mid- and high-volume labs. 

cobas^® infinity POC solution supports the growth of digital transformation in point of care testing.

cobas^® infinity POC solution is an integrated web-based application with open connectivity that helps manage point of care testing from a single location. This open software solution integrates with both Roche and non-Roche devices and with hospital and laboratory information systems, including HIS, LIS, HR, LMS and EMR systems.

Available for desktop, tablet and mobile (iOS and Android) devices, the solution features a user-friendly interface developed by design experts who have worked alongside POCCs and tailored the user interface to their workflows.  

With the CLIA-waived cobas^® Liat^® PCR System, clinicians are able to make optimal treatment decisions precisely when patients need them most. This is made possible with:

• PCR accuracy
• Quick, definitive results in 20 minutes or less (no need for interpretation)
• Fast, easy operation (walkaway after 1 minute hands-on time)

There are currently three CLIA-waived tests that can be performed in 20 minutes or less:

• cobas Liat Influenza A/B — comprehensive strain coverage
• cobas Liat Influenza A/B and RSV — one test, one sample, three results, zero age restrictions
• cobas Liat Strep A — no confirmation required

Consider what accurate and actionable results would do for you, your institution and your patients.   

The cobas^® prime Pre-analytical System* is designed for automation, simplicity and flexibility for processing, including capping, decapping, and aliquoting. The system also features cross-contamination control of molecular samples, including women's health, microbiology and virology, for use in diagnostic testing. The standalone system features track-connectable modular configurations with one workflow for multiple sample types, end-to-end automation with predictable turnaround time, and IT integration with sample and test tracking.

* The cobas^® prime Pre-analytical System is in development and not available for use in the United States

The cobas^® pro integrated solution provides fast turnaround time and simplified operations, allowing you to achieve excellence in patient care. The new and smart concept of self-operating maintenance executes tasks automatically in the background to support a reduction in the manual burden of daily maintenance. The new reagent carrier requires no operator preparation and provides up to 6 months of onboard stability for chemistry and up to 4 months of onboard stability for immunoassay. The cobas^® pro integrated solution continues Hitachi’s legacy of reliable systems, which enables smooth workflows and fewer unplanned interruptions. The cobas^® pro integrated solution is pending a 510(k) submission with the FDA and is not available in the U.S.

Roche is pleased to introduce the new Elecsys® Tacrolimus assay for the in vitro quantitative determination of tacrolimus in EDTA human whole blood. This assay is available across the Elecsys family of analyzers, bringing additional consolidation and testing efficiency from niche analyzers to the core of the laboratory with 24/7 availability. The Elecsys Tacrolimus assay demonstrates high precision across the entire measuring range (0.75-30 ng/mL) and has excellent comparability to LC-MS/MS. Offering the lowest functional sensitivity available on an automated immunoassay platform, the Elecsys Tacrolimus assay enables clinicians to make effective treatment decisions based on trusted, reliable results.

With the help of Roche’s high-sensitive* Elecsys® Troponin T Gen 5 STAT, your emergency department will be able to rule in or rule out myocardial infarction earlier¹ to optimize patient care and help achieve key quality measures.  Adoption of TnT Gen 5 STAT can also reduce rule-out uncertainty to help decrease the chances for 30-day readmission.

Roche has the expertise to help make TnT Gen 5 STAT adoption a success.  Over 300 sites are clinically using TnT Gen 5 STAT, including US News & World Report’s #1 and #2 Best Hospitals for Cardiology² and 5 of the Top 10 Best Hospitals for Cardiology.²

Implementing high-sensitive Elecsys TnT Gen 5 STAT could help support better care for your patients—and your institution’s bottom line. 

At Roche Diagnostics, we offer Roche Healthcare Consulting—providing personalized consultancy for your organization at every step of the way, from the first assessment phase through implementation and beyond for continuous improvements. Our consultants work with your team to optimize operational performance, maximize resource utilization and enhance your value to stakeholders. We enable your organization to become or remain competitive in the business of delivering healthcare and discover how to evolve to drive choice while staying ahead. Throughout the consulting process, we support you to improve outcomes and transform the way your health systems work in an ever-changing world of health policies and economics.  

The VENTANA PD-L1 (SP142) Assay enables you to reliably identify triple-negative breast cancer (TNBC) patients eligible for TECENTRIQ^® (atezolizumab) immunotherapy treatment.^1,2   It is the first and only assay with FDA approval to evaluate breast cancer patients for PD-L1 expression using immune cell staining and scoring within the tumor microenvironment.

Intended for use on the VENTANA BenchMark ULTRA IHC/ISH staining system, the fully automated assay can help you increase the efficiency of your breast cancer testing, enhance clinical confidence and improve patient care.

¹TECENTRIQ Prescribing Information
²Ventana Product Document Library. VENTANA PD-L1 (SP142) Assay Package Insert

Healthcare is evolving. Organizations must develop a data-driven mindset to drive value and impact their outcomes. With approximately 13 billion laboratory tests performed yearly, laboratory testing is the single highest volume medical activity in the U.S. It supplies the basis for 70% of all downstream medical decisions. At Roche, we believe utilizing the untapped resource of diagnostic data with the VIEWICS Dx Optimization solution will allow the lab to play a leading role in the evolution of healthcare in this rapidly changing, data-driven world.